Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results

Atara Biotherapeutics (NASDAQ:ATRA) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84, Zacks reports. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the business earned ($16.50) earnings per share.

Atara Biotherapeutics Price Performance

Shares of NASDAQ ATRA traded down $0.30 during midday trading on Thursday, reaching $13.96. The company’s stock had a trading volume of 43,751 shares, compared to its average volume of 106,571. The stock has a market capitalization of $68.54 million, a P/E ratio of -0.55 and a beta of 0.50. The firm has a 50 day moving average price of $8.89 and a 200-day moving average price of $10.30. Atara Biotherapeutics has a 12-month low of $6.50 and a 12-month high of $39.50.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. The Goldman Sachs Group decreased their price objective on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a report on Wednesday, July 17th. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price target for the stock from $25.00 to $18.00 in a report on Friday, August 16th. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Finally, Canaccord Genuity Group lifted their price objective on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Atara Biotherapeutics currently has an average rating of “Hold” and an average price target of $16.67.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.